Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress

Rhea-AI Summary

Bausch + Lomb (NYSE/TSX: BLCO), a global leader in eye health, announced the presentation of new data at the European Dry Eye Society (EuDEC) 2024 Congress in Madrid, Spain, from June 20-22. The event will feature multiple scientific presentations and educational sessions focusing on patient-centric approaches to dry eye disease. Key presentations include studies on preservative-free formulations, ocular vasoconstrictors, treatment landscapes, and the use of narrative medicine in understanding the disease's impact on quality of life. Notable sessions will cover innovations in clinical diagnosis, technological advancements, and patient communication.

Positive

• Bausch + Lomb is presenting new data, showcasing their commitment to innovation in eye care.
• Multiple studies will be presented, highlighting the company’s diverse eye care portfolio.
• Educational sessions will focus on patient-centric approaches and technological advancements in dry eye treatment.
• The company is addressing unmet needs and exploring the burden of dry eye disease through narrative medicine.

Negative

• The press release does not provide specific financial or clinical outcomes, making it difficult to assess the immediate business impact.
• There is no mention of commercial products being launched or any direct revenue impact from the presented data.

Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22.

Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from the company’s broad eye care portfolio, in addition to evaluations of the dry eye treatment landscape and overall disease burden.

Educational sessions will feature innovations in clinical diagnosis and treatment of dry eye, including technological advancements.

The complete list of Bausch + Lomb scientific presentations as well as details for the featured education events is as follows:

Poster Presentations

• “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Orobia et al.
• “Ocular Vasoconstrictors: Does Mechanism of Action Make a Difference?” Siebelmann et al.
• “Conjunctival Hyperemia: Healthcare Professionals’ Perspectives on the Treatment Landscape in Europe.” Borges et al.
• “Comparison of Two Preservative-Free Artificial Tears with Sodium Hyaluronate for Relief of Dry Eye: Multicenter Trial Findings.” Labetoulle et al.
• “Using Narrative Medicine to Identify Key Factors Affecting Quality of Life in Dry Eye Disease.” Rolando et al.

Oral Presentation

Saturday, June 22

• “Patient Communication and Unmet Needs Session: Narrative Medicine in Dry Eye - Exploring the Burden of the Disease”
  Maurizio Rolando, MD
  09:00-09:10 a.m. CEST; Conference Room 1

Featured Education Events

Saturday, June 22

• “Innovating with Bausch + Lomb: Driving Breakthroughs in Ophthalmic Technology”
  Mohamed Yassine, MD, Bausch + Lomb Vice President, Global Medical & Scientific Affairs
  11:30-12:00 p.m. CEST; Conference Room 2
• “The Patient-Centric Approach to Dry Eye: Innovations in Clinical Diagnosis and Treatment”
  1:45-2:30 p.m. CEST; Conference Room 1
  Prof. José Benítez-del-Castillo

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

© 2024 Bausch + Lomb.
MTB.0240.USA.24

View source version on businesswire.com: https://www.businesswire.com/news/home/20240617086661/en/

Media Contact:

Caryn Marshall

caryn.marshall@bausch.com

(908) 493-1381

Investor Contact:

George Gadkowski

george.gadkowski@bausch.com

(877) 354-3705 (toll free)

(908) 927-0735

Source: Bausch + Lomb Corporation

FAQ

What is the focus of Bausch + Lomb's presentation at the European Dry Eye Society 2024 Congress?

Bausch + Lomb will present new data focusing on patient-centric approaches to dry eye disease, including innovations in clinical diagnosis and treatment.

When and where is the European Dry Eye Society 2024 Congress taking place?

The EuDEC 2024 Congress will be held in Madrid, Spain, from June 20 to June 22.

What are some of the key studies Bausch + Lomb will present at the EuDEC 2024 Congress?

Key studies include evaluations of preservative-free formulations, ocular vasoconstrictors, treatment landscapes, and the impact of dry eye disease on quality of life.

How is Bausch + Lomb addressing the burden of dry eye disease?

Bausch + Lomb is using narrative medicine to explore the burden of dry eye disease and improve patient communication.

What type of innovations will be discussed at Bausch + Lomb's educational sessions?

Innovations in clinical diagnosis and treatment of dry eye, as well as advancements in ophthalmic technology, will be discussed.